A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study

Table 2

Inclusion and exclusion criteria for the study.

Inclusion criteria	Exclusion criteria
Healthy subjects with chronic alcohol consumption	Subjects abstaining from alcohol for more than 1 month, concomitant symptomatic or asymptomatic bacterial infection and severe bacterial infection within the previous 3 months
Elevated liver function markers-; Increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP)]; AST:ALT > 2	Subjects diagnosed with any diseases, and those with renal disorder, hepatitis (ALT level ≥ 3 times the upper limit), and gall bladder diseases or its removal, cardiovascular, pulmonary, kidney disease, pancreatitis, type I diabetes.
No evidence of liver diseases-; no evidence of liver diseases due to viral hepatitis, autoimmune disease, hemochromatosis, Wilson’s disease or drug-induced hepatitis	Subjects who are currently under any medications or herbal supplements.